Tri- Or Tetrasaccharide Patents (Class 514/61)
-
Publication number: 20030045505Abstract: The invention concerns a composition comprising at least a first constituent which is an oligosaccharide of formula (I) containing 3 to 5 oside units and having at least a D-galactose unit bound by an &agr;[1-6] bond with a sucrose unit. The invention is characterized in that in said sucrose unit R1, R2, R3, R4, independently of one another represent a hydrogen atom, an alkyl group containing 1 to 10 carbon atoms and optionally having at least an unsaturation, a sulphate function or else an ose and, at least a second constituent which is a molecule positively charged with a physiological pH and stimulating pinocytosis or a molecule stimulating membrane penetration.Type: ApplicationFiled: June 19, 2002Publication date: March 6, 2003Inventors: Gerard Martinez, Christian Francisco
-
Publication number: 20030040503Abstract: The subject invention relates to monovalent oligosaccharides and their use, for example, in the treatment and prevention of mammalian disease caused by infection with Shiga toxin (ST) or Shiga-like toxin (SHL). In particular, the trisaccharide globotriose (i.e., galactose &agr;1,4 galactose &bgr;1,4 glucose) may be used to competitively inhibit binding of the toxins to their cellular targets.Type: ApplicationFiled: May 24, 2001Publication date: February 27, 2003Inventors: James L. Leach, Stacey A. Garber, Pedro A. Prieto
-
Publication number: 20030040492Abstract: A prebiotic for enhancement of an immune response, a nutritional composition for enhancement of an immune response; use of a prebiotic in the manufacture of a medicament or nutritional composition for enhancement of an immune response; use of a prebiotic in the manufacture of a medicament or nutritional composition for the prevention or treatment of measles; a method of enhancing an immune response which comprises administering an effective amount of a prebiotic; and a method of prevention or treatment of measles which comprises administering an effective amount of a prebiotic. In preferred embodiments the prebiotic comprises a fructo-oligosaccharide.Type: ApplicationFiled: August 26, 2002Publication date: February 27, 2003Inventors: Ferdinand Haschke, Anne-Lise Carrie, Zdenek Kratky, Harriet Link-Amster, Florence Rochat
-
Patent number: 6503885Abstract: Carboxymethylgalactose derivatives represented by general formula (1); and salts thereof, which exhibit reactivity to selectins and are useful as inhibitors against selectin-related diseases such as various inflammations and cancerous metastasis; In said formula, R is a group rep resented by formula (1a), (1b) or (1c).Type: GrantFiled: March 20, 2001Date of Patent: January 7, 2003Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Makoto Kiso, Hideharu Ishida
-
Patent number: 6492341Abstract: The present invention describes isolated Fagopyritol A1, isolated Fagopyritol A3, and isolated Fagopyritol B3. Compositions which include two or more of Fagopyritol A1, Fagopyritol A2, Fagopyritol A3, Fagopyritol B1, Fagopyritol B2, Fagopyritol B3, and D-chiro-inositol, at least one of which is an isolated Fagopyritol A1, isolated Fagopyritol A3, or isolated Fagopyritol B3, are also disclosed. Methods for preparing substantially pure Fagopyritol A1, Fagopyritol A3, Fagopyritol B3, or mixtures thereof from buckwheat are also described. The fagopyritols can be used to prepare pharmaceutical compositions, the administration of which can be used to treat diabetes.Type: GrantFiled: May 25, 2000Date of Patent: December 10, 2002Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Marcin Horbowicz
-
Patent number: 6476005Abstract: An oral and injectable composition for mammals comprising a salt of glucosamine, such as glucosamine hydrochloride, sulfate, nitrate, or iodide, a chondroitin sulfate, hydrolyzed or native collagen, a sodium hyaluronate, chelated manganese ascorbate, and L-malic acid in powder form for oral ingestion or in a solution of sterilized water for injection. The composition acts as a chondroprotective agent which provides foundational support for the creation of new body tissue and cartilage growth in humans and animals. Other beneficial physiological properties include the enhancement of chondrocyte synthesis, the healing of chronic or acute wounds, the maintenance of healthy muscle and tissue, increasing the desirable concentration of hyaluronic acid, and anti-inflammatory activity.Type: GrantFiled: July 26, 1999Date of Patent: November 5, 2002Inventors: George D. Petito, Anita M. Petito
-
Publication number: 20020151520Abstract: Methods of promoting angiogenesis are provided which include administering to a suitable locus a cross-linked polysaccharide having a positive charge. Preferred cross-linked polysaccharides are biodegradable beads. A positive charge may be provided by diethylaminoethyl (DEAE) groups associated with the polysaccharide.Type: ApplicationFiled: March 23, 2000Publication date: October 17, 2002Inventor: Elliott A. Gruskin
-
Patent number: 6465434Abstract: Methods and compositions are disclosed for the inhibition of cancer metastases mediated by endothelial adhesion molecules. The present invention discloses that sialyl Lea and di-sialyl Lea, which are expressed at the surface of cancer cells, function as a binding partner for LEC-CAMs, such as ELAM-1, which are expressed at the surface of endothelial cells. The present invention also discloses that LEC-CAMs, such as ELAM-1, involved in cancer metastasis share a carbohydrate domain common to both sialyl Lea and sialyl Lex. Antibodies, saccharides, glycoconjugates, enzyme inhibitors and other compounds may be used in the methods of the present invention to inhibit the binding of malignant cells to endothelial cells for a variety of purposes in vivo and in vitro.Type: GrantFiled: November 23, 1999Date of Patent: October 15, 2002Assignees: Stanford UniversityInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Publication number: 20020147159Abstract: The present invention is directed towards a method and composition for controlled release acarbose formulations. The method and composition disclosed herein combine acarbose and a sustained release matrix. The administration of acarbose alone has been shown to be useful in the treatment of diabetes. Although the initial studies conducted herein were conducted with a delayed release formulation that allowed partial sustained release administered to stimulate sustained release, all indicators from the present invention suggest the formulation of acarbose in a sustained release formulation would have heretofore unexpected benefits. In a sustained release formulation, the ingredient(s) would be a shaped dosage unit having a sustained and regular release of acarbose throughout the small intestine where carbohydrates as a simple sugar are absorbed.Type: ApplicationFiled: April 10, 2001Publication date: October 10, 2002Inventor: James U. Morrison
-
Publication number: 20020142945Abstract: Methods for modulating immune responses, in particular IgE responses, are provided. The methods involve contacting an cell with an agent comprising multivalent lacto-N-neotetraose (LNnT), which modulates an immune response. The methods are useful for enhancing production of non-specific polyclonal IgE, inhibiting production of antigen-specific IgE responses, inducing cytokine production, and stimulating proliferation of splenocytes. In a preferred embodiment, the invention provides methods for modulating an immune response to an antigen (e.g., an allergan) in vivo. Pharmaceutical compositions for modulating immune responses comprising the agents of the invention are also provided.Type: ApplicationFiled: December 19, 2001Publication date: October 3, 2002Applicant: President and Fellows of Harvard CollegeInventors: Donald A. Harn, Mitsuhiro Okano
-
Publication number: 20020137725Abstract: A method for promoting cardiovascular health of a mammal in need thereof, comprising administering to said mammal an efficacious amount of tagatose to raise the HDL level of said mammal.Type: ApplicationFiled: March 20, 2001Publication date: September 26, 2002Inventor: Gilbert V. Levin
-
Patent number: 6455512Abstract: Emulsifiers based on the reaction product of hydrocolloid and dicarboxylic anhydrides, especially useful in the preparation of oil-in-water emulsions.Type: GrantFiled: March 5, 2001Date of Patent: September 24, 2002Assignee: TIC Gums, Inc.Inventor: Florian Magno Ward
-
Patent number: 6451767Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10, are each, independently, hydrogen, acyl of 2-7 carbon atoms, perfluoroacyl of 2-10 carbon atoms, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, benzoyl, benzyl or —SO3M; M is hydrogen, lithium, sodium, potassium or ammonium; R11 is hydrogen, alkyl of 1-6 carbon atoms, perfluoroalkyl of 1-6 carbon atoms, halogen, nitrile, nitro, or alkoxy of 1-6 carbon atoms; R12 is hydrogen, nitro, amino, acylamino of 2-7 carbon atoms, perfluoroacylamino of 2-7 carbon atoms, alkylamino of 1-6 carbon atoms, perfluoroalkylamino of 1-6 carbon atoms, dialklylamino where each alkyl chain is independently 1-6 carbon atoms, perfluorodialklylamino where each alkyl chain is independently 1-6 carbon atoms alkylsulfonylamino of 1-6 carbon atoms, perfluoroalkylsulfonylamino of 1-6 carbon atoms, arylsulfonylamino of 6-10 carbon atoms or arylsulfonylaminType: GrantFiled: July 11, 2001Date of Patent: September 17, 2002Assignee: WyethInventor: Paul J. Dollings
-
Patent number: 6444655Abstract: The present invention relates to simplified synthesis, new carbohydrate-based products and practical use of different carbohydrate-based products. Examples of these are (Gal&agr;1-3Gal), GlcNAc&bgr;1-3Gal, &agr;- or &bgr;-glycosides thereof, Gal&agr;1-3Gal- containing tri-, or higher oligosaccharides, &agr;- or &bgr;-glycosides thereof, GlcNAc&bgr;1-3Gal containing tri-, tetra-, or higher oligosaccharides, and derivatives and/or &agr;- or &bgr;-glycosides thereof, Gal&agr;1-3GalGlcNAc&bgr;1-3Gal, &agr;- or &bgr;-glycosides thereof, Gal&agr;1-3Gal&bgr;1-4GlcNAc&bgr;1-3Gal&bgr;1-4Glc, or other higher oligosaccharides containing the Gal&agr;1-3Gal-structure, &agr;- or &bgr;-glycosides thereof, modified carbohydrates, di-, tri-, oligo-, or polyfunctional products containing carbohydrate structures, and the use of the products for synthesis, affinity purification, diagnostic applications and therapy.Type: GrantFiled: June 19, 1998Date of Patent: September 3, 2002Assignee: Procur ABInventor: Kurt Nilsson
-
Publication number: 20020115634Abstract: Cold storage solutions for the preservation of organs and biological tissues prior to implantation, including a cellular energy production stimulator under anaerobic conditions, an anti-inflammatory agent, and an oxygen free radical scavenger.Type: ApplicationFiled: October 12, 2001Publication date: August 22, 2002Applicant: Pike Laboratories, Inc.Inventors: Maximilian Polyak, Ben O?apos;Mar Arrington
-
Patent number: 6436446Abstract: A method including administering a beverage composition suitable for human consumption including effective amounts of the following solubilized components, a calcium compound, an organic acid in an amount up to the equivalent amount of a calcium of the calcium compound, an isoflavone, and inulin wherein the effective amounts are sufficient to reduce the risk of bone density loss and are solubilized by a stabilizing agent including one or more of maltol, carrageenan and maltodextrin, and xanthan gum.Type: GrantFiled: July 30, 1999Date of Patent: August 20, 2002Assignee: Pharmavite LLCInventors: Samuel L. Forusz, Hanlan Liu, Rose M. Muatine
-
Patent number: 6436911Abstract: An IL-12 production inhibitor which comprises, as an active ingredient, a keratan sulfate oligosaccharide or a derivative thereof, for example, a keratan sulfate oligosaccharide comprising at least one repeating unit of either one of the disaccharides represented by the following formulas: Gal (6s)-GlcNAc (6s) and Gal (6s)-GlcNAc wherein Gal represents a galactose residue, GlcNAc represents an N-acetylglucosamine residue, 6s indicates that 6-0-sulfate ester is formed at a Hydroxyl group at the 6-position, and - represents a glycosidic linkage.Type: GrantFiled: July 21, 2000Date of Patent: August 20, 2002Assignee: Seikagaku CorporationInventors: Akira Asari, Hitoshi Kurihara, Heping Xu, Satoshi Miyauchi, Toshikazu Minamisawa
-
Patent number: 6399071Abstract: Polyamide conjugates comprising either (a) a xenoantigenic group; or (b) a biologically active group and a macromolecular, macro- or microscopic entity, bound to a polyamide backbone, processes for their preparation and the use of these conjugates in therapeutic compositions.Type: GrantFiled: October 14, 1999Date of Patent: June 4, 2002Assignee: Novartis AGInventors: Rudolf Duthaler, Andreas Katopodis, Willy Kinzy, Reinhold Öhrlein, Gebhard Thoma
-
Publication number: 20020064768Abstract: Cold storage solutions for the preservation of organs and biological tissues prior to implantation, including a prostaglandin having vasodilatory, membrane stabilizing, platelet aggregation prevention upon reperfusion, and complement activation inhibitory properties, a nitric oxide donor, and a glutathione-forming agent.Type: ApplicationFiled: October 12, 2001Publication date: May 30, 2002Applicant: Pike Laboratories, Inc.Inventors: Maximilian Polyak, Ben O?apos;Mar Arrington
-
Patent number: 6395717Abstract: Therapeutic drugs for endotoxin blood symptom and multi-organ failure induced by it is provided, which therapeutic during are composed of sialic acid its salt, polymers of sialic acid or a salt of the polymer as effective components and have high therapeutic effects for shock death and organ failure induced by endotoxin as well as high safety, and are effective for treatment of endotoxin-shock, and organ failure.Type: GrantFiled: January 23, 1997Date of Patent: May 28, 2002Assignees: NGK Insulatirs, Ltd., Biseiken Co., Ltd.Inventors: Michio Ohta, Takaaki Hasegawa, Masayuki Nadai, Yasuko Yoshida, Mitsuo Kawase, Tadahiko Inukai
-
Patent number: 6391857Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lympho-cytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1-X[Fuc&agr;1-y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration and for directing molecules to such sites.Type: GrantFiled: November 9, 1994Date of Patent: May 21, 2002Assignees: Stanford UniversityInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Patent number: 6387884Abstract: Novel methods and compositions are provided for modulating homing of leukocytes, particularly lymphocytes, where the compounds are cross-reactive with Neu5Ac2-3Gal&bgr;1−X[Fuc&agr;1−y]GlcNAc, where one of x and y is three and the other is four. These compounds may be administered to a host associated with inflammation, to avoid the deleterious effects of leukocyte infiltration.Type: GrantFiled: November 9, 1994Date of Patent: May 14, 2002Assignees: Stanford UniversityInventors: John L. Magnani, Eugene C. Butcher, Ellen L. Berg
-
Publication number: 20020049183Abstract: The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels.Type: ApplicationFiled: January 10, 2001Publication date: April 25, 2002Inventors: Saul Yedgar, David Shuseyov, Gershon Golomb, Reuven Reich, Isaac Ginsburg, Abd-al-Roof Higazi, Moshe Ligumski, Miron Krimsky, David Ojcius, Benito Antonio Yard, Fokko Johannes van der Woude, Edit Schnitzer
-
Publication number: 20020035088Abstract: Topically administrable aqueous solution compositions containing tobramycin and xanthan gum are disclosed. The solution compositions contain a buffering agent and a pH-adjusting agent in an amount sufficient to achieve a pH above 7.8 in order to minimize or avoid compatibility problems between tobramycin and xanthan gum.Type: ApplicationFiled: July 11, 2001Publication date: March 21, 2002Applicant: Alcon Universal Ltd.Inventors: Nuria Carreras Perdiguer, Jose Alberto Vallet Mas, Gemma Torrella Cabello
-
Patent number: 6358930Abstract: This invention relates to prevention and/or treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD), pseudomembranous colitis (PMC) and other conditions associated with C. difficile infection, using oligosaccharide compositions which bind C. difficile toxin B. More specifically, the invention concerns neutralization of C. difficile toxin B associated with such conditions.Type: GrantFiled: November 4, 1999Date of Patent: March 19, 2002Assignee: Synsorb Biotech Inc.Inventors: Louis D. Heerze, Glen D. Armstrong
-
Publication number: 20020022602Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure 1Type: ApplicationFiled: July 11, 2001Publication date: February 21, 2002Applicant: American Home Products CorporationInventor: Paul J. Dollings
-
Patent number: 6346519Abstract: This invention relates to the composition and method of treating arthritis, repairing of articular joint surfaces and the relief of symptoms associated with arthritis. The composition comprises a nitric oxide synthase inhibitor and amino sugars. The nitric oxide synthase inhibitor reduces the level of nitric oxide, the free radical believed responsible for the degradation of articular cartilage. Amino sugars are the building blocks of articular cartilage and have anti-inflammatory actions.Type: GrantFiled: July 8, 1999Date of Patent: February 12, 2002Assignee: Advanced Medical InstrumentsInventor: Edward J. Petrus
-
Patent number: 6310043Abstract: Compounds which bind to toxins associated with enteric bacterial infection, compositions including the compounds, methods for the neutralization of toxins in a patient, and methods for the diagnosis of bacterial and viral infections are disclosed. Toxins which can be bound by the compounds include pentameric toxins, for example SLTs, such as those from salmonella, camylobacter and other bacteria, verotoxins from E. coli, cholera toxin, clostridium difficile toxins A and B, bacterial pili from enteropathogenic E. coli (EPEC) and enterotoxigenic E. coli (ETEC) and viral lectins such as viral hemagglutinins. The compounds include a core molecule bound to a plurality of linker arms, which in turn are bound to a plurality of bridging moieties, which in turn are bound to at least one, and preferably, two or more ligands which bind to the toxin. The presence of a plurality of bridged dimers of the ligands is responsible for the increased binding affinity of the compounds relative to the ligands themselves.Type: GrantFiled: May 24, 1999Date of Patent: October 30, 2001Assignee: Governors of the University of AlbertaInventors: David R. Bundle, Pavel Kitov, Randy J. Read, Hong Ling, Glen Armstrong
-
Publication number: 20010034335Abstract: Apoptosis inducers, anticancer drugs and carcinostatic drugs containing sulfated-fucose-containing polysaccharide(s) and/or degradation product(s) thereof, and a method for inducing apoptosis by using sulfated-fucose-containing polysaccharide(s) and/or degradation product(s) thereof as the active ingredient. A degrading enzyme which is useful in the production of the degradation products of sulfated-fucose-containing polysaccharides.Type: ApplicationFiled: January 29, 2001Publication date: October 25, 2001Inventors: Takeshi Sakai, Hideo Kitano, Fu-Gong Yu, Shinji Nakayama, Kaoru Kojima, Hitomi Kimura, Yoshikuni Nakanishi, Kaoru Katayama, Takanari Tominaga, Kazuo Shimanaka, Katsushige Ikai, Ikunoshin Kato
-
Publication number: 20010031459Abstract: The invention relates to the field of organ and tissue perfusion. More particularly, the present invention relates to a method for preparing organs, such as the kidney and liver, for cryopreservation through the introduction of vitrifiable concentrations of cryoprotectant into them. To prepare the organ for cryopreservation, the donor human or animal, is treated in the usual manner and may also be treated with iloprost, or other vasodilators, and/or transforming growth factor &bgr;1. Alternatively, or additionally, the organ which is to be cryopreserved can be administered iloprost, or other vasodilators, and/or transforming growth factor &bgr;1 directly into its artery. The invention also relates to preparing organs for transplantation by a method for the removal of the cryoprotectant therefrom using low (such as raffinose, sucrose, mannitol, etc.Type: ApplicationFiled: January 12, 2001Publication date: October 18, 2001Applicant: THE AMERICAN NATIONAL RED CROSSInventors: Gregory Fahy, Bijan Khirabadi, Yasumitsu Okouchi, Thomas Maciag
-
Patent number: 6303587Abstract: Composition for application, in particular to leaves, comprising an excipient, the conventional constituents of compositions for application, in particular to leaves, and an active ingredient, characterized by the fact that the active ingredient is constituted by at least one phytosanitary product capable of stimulating the germination of pollen grains, selected from the group comprising: oligosaccharides having a degree of polymerization up to 10 and comprising up to 10, preferably up to 5 and, even more preferably, two glucidic units linked by &bgr;1-3, &bgr;1-4 et &agr;1-3, particularly those of the group comprising laminaribiose, cellobiose, nigerose, laminaritriose, laminaritetraose and laminaripentaose, derivatives of the above oligosaccharides substituted on the free anomeric carbon atom or on all the carbon atoms having a free hydroxide by a radical selected from the group comprising: C1 to C5 alkyl radicals, preferably the methyl radical, C1 to C5 acyl radicals, preferably the acetyl radical, arType: GrantFiled: December 27, 1999Date of Patent: October 16, 2001Assignee: Laboratoires Goemar S.A.Inventors: Jean-Claude Yvin, Florence Levasseur, Kiem-Ngoc Tran Thanh, Van le Bui
-
Patent number: 6303580Abstract: The present invention provides for an isolated A-type substance having a structure identical to an A-type substance obtained from human liver or placenta, which is a cyclical containing carbohydrate comprising Zn2+ and related compositions.Type: GrantFiled: June 4, 1999Date of Patent: October 16, 2001Assignee: Rademacher Group LimitedInventors: Thomas William Rademacher, Hugo Caro
-
Patent number: 6299897Abstract: This invention provides compositions for inhibiting the binding between two cells, one expressing P- or L-selectin on the surface and the other expressing the corresponding ligand. A covalently crosslinked lipid composition is prepared having saccharides and acidic group on separate lipids. The composition is then interposed between the cells so as to inhibit binding. Inhibition can be achieved at an effective oligosaccharide concentration as low as 106 fold below that of the free saccharide. Since selectins are involved in recruiting cells to sites of injury, these composition scan be used to palliate certain inflammatory and immunological conditions.Type: GrantFiled: November 15, 1999Date of Patent: October 9, 2001Assignee: The Regents of the University of CaliforniaInventors: Jon O. Nagy, Wayne R. Spevak, Falguni Dasgupta, Caroline Bertozzi
-
Publication number: 20010024809Abstract: The present invention relates to the use of a compound having general formula (I) as described hereunder 1Type: ApplicationFiled: January 12, 2001Publication date: September 27, 2001Inventors: Anacleto Minghetti, Nicoletta Crespi Perellino, Aldo Roda, Bruno Danieli, Giuliano Frigerio, Danila Ingrid Marchioretto
-
Patent number: 6281202Abstract: The present invention discloses carbohydrates and carbohydrate analogs that bind to epidermal growth factor (EGF) receptors. Methods of using such carbohydrates or analogs for a variety of uses related to the EGF receptor are also provided. In preferred aspects of the present invention, methods for killing or inhibiting the growth of tumor cells with increased EGF receptor activity are disclosed.Type: GrantFiled: August 23, 1999Date of Patent: August 28, 2001Assignee: GlycoTech Corp.Inventors: John L. Magnani, Eric G. Bremer
-
Patent number: 6271204Abstract: The present invention provides for an isolated P-type substance having a structure identical to a P-type substance obtained from human liver or placenta, which is a cyclitol containing carbohydrate comprising Mn2+ and Zn2+ and related compositions.Type: GrantFiled: June 14, 1999Date of Patent: August 7, 2001Assignee: Rademacher Group LimitedInventors: Thomas William Rademacher, Hugo Caro
-
Patent number: 6245752Abstract: Methods and compositions are provided for tolerizing shed antigen-specific B cells involved in an immune complex-mediated disease progression. The composition comprises a substantially non-immunogenic carrier molecule to which is linked carbohydrate chains containing a suppressive amount of a repeated, antigenic carbohydrate determinant derived from a shed antigen of interest. In a method of tolerizing shed antigen-specific B cells involved in an immune complex-mediated disease progression, administered to an individual is a therapeutically effective amount of the composition which, when contacting the shed antigen-specific B cells, induces tolerization of the shed antigen-specific B cells.Type: GrantFiled: April 26, 1999Date of Patent: June 12, 2001Assignee: BioCrystal Ltd.Inventors: Emilio Barbera-Guillem, M. Bud Nelson
-
Patent number: 6245744Abstract: Substituted propanolamine derivatives, their pharmaceutically tolerated salts and physiologically functional derivatives thereof are described. Also described are compounds of formula I in which the radicals have the abovementioned meanings, and their physiologically tolerated salts, physiologically functional derivates and processes for their preparation. The compounds are suitable as, for example, hypolipidemics.Type: GrantFiled: October 1, 1999Date of Patent: June 12, 2001Assignee: Aventis Pharma Deutschland GmbHInventors: Wendelin Frick, Reinhard Kirsch, Heiner Glombik, Werner Kramer, Hans-Ludwig Schäfer
-
Patent number: 6235309Abstract: This invention relates generally to the field of therapeutic compounds designed to interfere between the binding of ligands and their receptors on cell surface. More specifically, it provides products and methods for inhibiting cell migration and activation using lipid assemblies with surface recognition elements that are specific for the receptors involved in cell migration and activation.Type: GrantFiled: February 27, 1998Date of Patent: May 22, 2001Assignee: The Regents of the University of CaliforniaInventors: Jon O. Nagy, Robert F. Bargatze
-
Patent number: 6232450Abstract: A new class of N-linked Lewis and LacNAc analogs of are synthesized and shown to be effective inhibitors of human fucosyltransferases. In a high yielding reaction sequence the glucosamine derivative 1 was transformed to the 3-azido-2,3-dideoxy sugar 2e under excellent stereocontrol. The LacNAc analog 4d was synthesized as a single isomer in three steps starting from 2e. In a one pot procedure iminocyclitol 5 was transformed into aldehyde 6 and successfully used for reductive amination with 4c and 2f yielding trisaccharide 8a, and disaccharide 7a.Type: GrantFiled: June 7, 1999Date of Patent: May 15, 2001Assignee: The Scripps Research InstituteInventor: Chi-Huey Wong
-
Patent number: 6224891Abstract: This invention relates to the treatment of diarrhea and related conditions caused by pathogenic E. coli infection. More specifically, this invention is drawn to the unexpected discovery that by administering a composition which binds and removes the shiga like toxins (SLT) produced by pathogenic E. coli whenever an antibiotic is administered, improved treatment is provided. Novel compositions containing both antibiotic and toxin binding composition and methods of treatment which use simultaneous administration toxin binding composition whenever antibiotic is administered are provided. These compositions and methods kill the enteric E. coli organisms which produce the conditions and neutralize the SLT produced by the organisms and/or released from the organisms when they are killed. Thus, these compositions and methods are better able to ameliorate the symptoms of the infection and inhibit progression of this infection into hemolytic uremic syndrome (HUS) than conventional treatment.Type: GrantFiled: February 23, 1999Date of Patent: May 1, 2001Assignee: Synsorb Biotech, Inc.Inventors: David John Rafter, Robert Murray Ratcliffe, Bradley G. Thompson, Glen D. Armstrong
-
Patent number: 6207652Abstract: Apoptosis inducers, anticancer drugs and carcinostatic drugs containing sulfated-fucose-containing polysaccharide(s) and/or degradation product(s) thereof, and a method for inducing apoptosis by using sulfated-fucose-containing polysaccharide(s) and/or degradation product(s) thereof as the active ingredient. A degrading enzyme which is useful in the production of the degradation products of sulfated-fucose-containing polysaccharides.Type: GrantFiled: April 9, 1998Date of Patent: March 27, 2001Assignees: Takara Shuzo Co., Ltd., Research Institute for GlycotechnologyInventors: Takeshi Sakai, Hideo Kitano, Fu-Gong Yu, Shinji Nakayama, Kaoru Kojima, Hitomi Kimura, Yoshikuni Nakanishi, Kaoru Katayama, Takanari Tominaga, Kazuo Shimanaka, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 6197568Abstract: Methods and compositions for the isolation, diagnosis and treatment of microorganisms such as flaviviruses and other hemorrhagic fever viruses are based on the sulfated polyanion-dependent interaction of flaviviruses and hemorrhagic fever viruses, in particular dengue virus, with target cells. The cellular receptors targeted by these viruses have been identified as sulfated polyanionic glycoproteins, that include highly sulfated heparan sulfate glycosaminoglycans for some target cell types, and as a sulfated mucin on vascular endothelium. Compounds such as heparin, highly sulfated heparan sulfate, and synthetic polyanions such as Suramin, inhibit the interaction between the microorganisms and target cells, thereby disrupting the infective process.Type: GrantFiled: July 28, 1998Date of Patent: March 6, 2001Assignee: The Regents of the University of MichiganInventors: Rory M. Marks, Yaping Chen, Terence Maguire, Robert J. Linhardt
-
Patent number: 6187754Abstract: Sialyl-Lewisa and sialyl-Lewisx epitope analogues, in which the natural N-acetyl group of the N-acetylglucosamine monomer is replaced by various hydroxylated aromatic substituents.Type: GrantFiled: January 8, 1999Date of Patent: February 13, 2001Assignee: GlycoTech Corp.Inventor: Reinhold Oehrlein
-
Patent number: 6169077Abstract: Sialyl-Lewisx and sialyl-Lewisa epitope analogues in which the naturally occurring N-acetyl group of the N-acetylglucosamine monomer is replaced by various aliphatic or aromatic substituents and the L-fucose naturally present is replaced by various naturally occurring or non-naturally occurring sugars.Type: GrantFiled: February 11, 1999Date of Patent: January 2, 2001Assignee: GlycoTech Corp.Inventor: Reinhold Oehrlein
-
Patent number: 6162795Abstract: The present invention describes isolated Fagopyritol A1, isolated Fagopyritol A2, and isolated Fagopyritol B3. Compositions which include two or more of Fagopyritol A1, Fagopyritol A2, Fagopyritol B1, Fagopyritol B2, Fagopyritol B3, and D-chiro-inositol, at least one of which is an isolated Fagopyritol A1, isolated Fagopyritol A2, or isolated Fagopyritol B3, are also disclosed. Methods for preparing substantially pure Fagopyritol A1, Fagopyritol A2, Fagopyritol B1, Fagopyritol B2, Fagopyritol B3, or mixtures thereof from buckwheat are also described. The fagopyritols can be used to prepare pharmaceutical compositions, the administration of which can be used to treat diabetes.Type: GrantFiled: May 6, 1998Date of Patent: December 19, 2000Assignee: Cornell Research Foundation, Inc.Inventors: Ralph L. Obendorf, Marcin Horbowicz
-
Patent number: 6159954Abstract: A keratan sulfate oligosaccharide which comprises from two to five sugar units and has sulfated N-acetylglucosamine at the reducing end and in a molecule of which at least two hydroxyl groups are sulfated, preferably, which contains at least disaccharide represented by the formula Gal(6S)-GlcNAc(6S) (in the formula, Gal, GlcN, Ac, and 6S represent a galactose, a glucosamine, an acetyl group, and a 6-O-sulfate ester, respectively) as a constitutional ingredient, and/or pharmaceutically acceptable salt thereof are used as active ingredients of anti-inflammatory agents, antiallergic agents, immunomodulators, cell differentiation inducers, and apoptosis inducers.Type: GrantFiled: May 24, 1999Date of Patent: December 12, 2000Assignee: Seikagaku CorporationInventors: Hiroshi Maruyama, Kiyoshi Morikawa, Akira Tawada, Satoshi Miyauchi, Keiichi Yoshida, Akira Asari
-
Patent number: 6150568Abstract: Disclosed is the compound valiolone, which has the formula (I): ##STR1## a method of preparing valiolone, and a method of using valiolone to prepare acarbose and voglibose.Type: GrantFiled: March 30, 1999Date of Patent: November 21, 2000Assignee: University of WashingtonInventors: Heinz G. Floss, Sungsook Lee, Ingo Tornus
-
Patent number: 6143730Abstract: Sulfated oligosaccharides, wherein the oligosaccharide has the general formula I:R.sub.1 --(R.sub.x).sub.n --R.sub.2 (I)wherein R.sub.1 and R.sub.2 and each R.sub.x represents a monosaccharide unit, all of which may be the same or different, adjacent monosaccharide units being linked by 1.fwdarw.2, 1.fwdarw.3, 1.fwdarw.4 and/or 1.fwdarw.6 glycosidic bonds and n is an integer of from 1 to 6, and use thereof as anti-angiogenic, anti-metastatic and/or anti-inflammatory agents.Type: GrantFiled: October 28, 1997Date of Patent: November 7, 2000Assignee: The Australian National UniversityInventors: Christopher Richard Parish, William Butler Cowden
-
Patent number: 6136790Abstract: The invention relates to carbohydrate mimetics, which inhibit the binding of selectin to carbohydrate ligands, of the formula I ##STR1## excluding the compounds sialyl-Lewis-X and -A and their derivatives which, instead of an N-acetyl group, carry the substituents N.sub.3, NH.sub.2 or OH or which, instead of fucose, carry glycerol,and pharmaceutical compositions and diagnostic agents containing these derivatives, and methods for using these pharmaceutical compositions and diagnostic agents.Type: GrantFiled: July 28, 1997Date of Patent: October 24, 2000Assignee: Glycorex ABInventors: Alexander Toepfer, Gerhard Kretzschmar, Eckart Bartnik, Dirk Seiffge